JP2023012503A5 - - Google Patents

Download PDF

Info

Publication number
JP2023012503A5
JP2023012503A5 JP2022172004A JP2022172004A JP2023012503A5 JP 2023012503 A5 JP2023012503 A5 JP 2023012503A5 JP 2022172004 A JP2022172004 A JP 2022172004A JP 2022172004 A JP2022172004 A JP 2022172004A JP 2023012503 A5 JP2023012503 A5 JP 2023012503A5
Authority
JP
Japan
Prior art keywords
cells
cik nkt
population
nkt cells
cik
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022172004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023012503A (ja
JP7664207B2 (ja
Filing date
Publication date
Priority claimed from JP2021500737A external-priority patent/JP7190022B2/ja
Application filed filed Critical
Publication of JP2023012503A publication Critical patent/JP2023012503A/ja
Publication of JP2023012503A5 publication Critical patent/JP2023012503A5/ja
Priority to JP2024202837A priority Critical patent/JP2025015816A/ja
Application granted granted Critical
Publication of JP7664207B2 publication Critical patent/JP7664207B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022172004A 2018-07-10 2022-10-27 臍帯血からのcik nkt細胞の作製方法 Active JP7664207B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024202837A JP2025015816A (ja) 2018-07-10 2024-11-21 臍帯血からのcik nkt細胞の作製方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862696131P 2018-07-10 2018-07-10
US62/696,131 2018-07-10
JP2021500737A JP7190022B2 (ja) 2018-07-10 2019-07-01 臍帯血からのcik nkt細胞の作製方法
PCT/US2019/040145 WO2020014029A1 (en) 2018-07-10 2019-07-01 Generating cik nkt cells from cord blood

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021500737A Division JP7190022B2 (ja) 2018-07-10 2019-07-01 臍帯血からのcik nkt細胞の作製方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024202837A Division JP2025015816A (ja) 2018-07-10 2024-11-21 臍帯血からのcik nkt細胞の作製方法

Publications (3)

Publication Number Publication Date
JP2023012503A JP2023012503A (ja) 2023-01-25
JP2023012503A5 true JP2023012503A5 (https=) 2023-06-22
JP7664207B2 JP7664207B2 (ja) 2025-04-17

Family

ID=67551410

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021500737A Active JP7190022B2 (ja) 2018-07-10 2019-07-01 臍帯血からのcik nkt細胞の作製方法
JP2022172004A Active JP7664207B2 (ja) 2018-07-10 2022-10-27 臍帯血からのcik nkt細胞の作製方法
JP2024202837A Pending JP2025015816A (ja) 2018-07-10 2024-11-21 臍帯血からのcik nkt細胞の作製方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021500737A Active JP7190022B2 (ja) 2018-07-10 2019-07-01 臍帯血からのcik nkt細胞の作製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024202837A Pending JP2025015816A (ja) 2018-07-10 2024-11-21 臍帯血からのcik nkt細胞の作製方法

Country Status (9)

Country Link
US (2) US11931382B2 (https=)
EP (1) EP3820994A1 (https=)
JP (3) JP7190022B2 (https=)
KR (3) KR102721222B1 (https=)
CN (2) CN119372142A (https=)
AU (2) AU2019300782B2 (https=)
CA (1) CA3105601C (https=)
IL (2) IL319500A (https=)
WO (1) WO2020014029A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220151184A (ko) * 2020-03-04 2022-11-14 바이오이클립스 테라퓨틱스, 인크. 활성화된 면역 세포의 제조 방법
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
CN111690607B (zh) * 2020-06-19 2022-02-18 珠海贝索细胞科学技术有限公司 一种高效杀伤细胞体外培养试剂盒及培养方法
CN112251407A (zh) * 2020-11-03 2021-01-22 广州康琪莱精准医疗科技有限公司 一种脐带血cik细胞的扩增培养方法
CN114807044B (zh) * 2021-04-30 2023-09-08 四川大学华西医院 一种具有高nkt细胞比例的car-cik细胞制备方法及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
WO1999024566A1 (en) 1997-11-06 1999-05-20 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
WO2000020460A1 (en) 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
US7098008B2 (en) 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
AU2001262697A1 (en) * 2000-06-06 2001-12-17 Kirin Beer Kabushiki Kaisha Method of amplifying natural killer t cells
EP1653977A2 (en) * 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
CN102575231B (zh) 2009-10-28 2013-09-11 宝生物工程株式会社 制备细胞因子诱导的杀伤细胞的方法
WO2011103882A1 (en) * 2010-02-24 2011-09-01 Ingo Schmidt-Wolf Method for the generation of a cik cell and nk cell population
WO2011163401A2 (en) 2010-06-22 2011-12-29 Neogenix Oncology, Inc. Colon and pancreas cancer specific antigens and antibodies
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
WO2013051718A1 (ja) 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
CN114134113A (zh) 2012-08-13 2022-03-04 人类起源公司 自然杀伤细胞及其用途
CN104769103B (zh) 2012-09-04 2018-06-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
US20170029777A1 (en) * 2014-01-27 2017-02-02 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
CN104017770B (zh) * 2014-06-23 2015-04-29 山东赛乐中德生物科技有限公司 一种利用糖脂制备cik细胞的方法
TWI702290B (zh) * 2015-04-07 2020-08-21 富禾生醫股份有限公司 經修飾之自然殺手t細胞、醫藥組合物及其用途
CN106434552B (zh) * 2015-08-13 2022-04-29 清华大学 新型nkt样细胞亚群及其治疗肿瘤的用途
CN105176927B (zh) * 2015-10-15 2019-01-18 丛秀丽 一种细胞毒性增强的高效靶向杀伤nk/cik细胞的制备方法
CN106566807A (zh) * 2016-10-21 2017-04-19 闾军 一种浓度梯度rhIL‑2依赖的iNKT细胞扩增方法及其应用
CN106434556B (zh) * 2016-11-22 2019-10-11 上海新长安生物科技有限公司 一种体外诱导扩增i型nkt细胞的方法
EP3634437A4 (en) * 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
CN114258305A (zh) * 2019-08-21 2022-03-29 阿克索治疗公司 Iii型nkt细胞及相关组合物和方法
CN111172110B (zh) * 2019-12-20 2022-04-22 中科细胞科技(广州)有限公司 一种脐带血cik细胞的培养方法

Similar Documents

Publication Publication Date Title
JP2023012503A5 (https=)
Spitzer et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus–associated lymphoma: AIDS Malignancy Consortium study 020
JP2010507567A5 (https=)
Dey et al. Current status of haploidentical stem cell transplantation
RU2009108289A (ru) Комбинированная терапия
FI3377534T3 (fi) Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää
JP2012532624A5 (https=)
Khalil et al. Biochemical and molecular docking-based assessment of Spirulina platensis's bioactive constituents for their potential application as natural anticancer drug
Hu The central THαβ immunity associated cytokine: IL-10 has a strong anti-tumor ability toward established cancer models in vivo and toward cancer cells in vitro
Poccia et al. Vγ9Vδ2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy
IL317199A (en) Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
Liu et al. The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo
Fatima et al. Allicin as an adjunct immunotherapy against tuberculosis
Parisi et al. Acute myelogenous leukemia: advances and limitations of treatment
Qadir et al. HIV-Plasmodium Co-infection: Malaria in AIDS patients.
Khwaza et al. Strategies for delivery of antiviral agents
Sakoda et al. Recurrent Subcutaneous Sweet's Disease in a myelofibrosis patient treated with ruxolitinib before allogeneic stem cell transplantation
Meneses-Sagrero et al. Natural compounds combined with imatinib as promising antileukemic therapy: An updated review
Lefrère et al. Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure
Nakasone et al. Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study
Visani et al. Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?
Xu et al. Current status of allogeneic hematopoietic cell transplantation for MDS
Kochupillai et al. Fetal liver infusion in acute myelogenous leukaemia
BALAMITHRA et al. Role of Natural Killer Cells in Innate Immunity-A Review.
FREI III children, with this approach. 14, 15